Luceiro Capital Companies

ESEN

Real companies with freely usable public data: official annual reports of European listed companies (ESEF), SEC accounts and ECB exchange rates. No share prices, so there is no market capitalisation, P/E or EV/EBITDA.

Company sheet · analysis as of 21/10/2026

AstraZeneca PLC

AZN · Health care · Pharmaceuticals · GB · reporting currency USD · LEI PY6ZZQWO2IZFZC3IOL08

Share: XLON · USD · GB0009895292 · Price: No data: no share prices up to the analysis date

Reference period: FY ended 31/12/2025, published on 04/03/2026

← Back to the ranking

Shareholder score without valuation

65

Coverage 100 %

Credit score

68

Coverage 100 %

Alerts

0

Screens passed: 1 of 1

Shareholder view

FactorValueCompared with PercentileWeightContribution
ROE 21.0 % Sector (6 companies) 75 17 % 12.5
ROIC 14.6 % Sector (7 companies) 64 17 % 10.7
Gross margin 81.9 % Universe (26 companies) 98 17 % 16.3
EBITDA margin 33.2 % Sector (7 companies) 64 17 % 10.7
Cash conversion 115.1 % Sector (7 companies) 21 17 % 3.6
Revenue growth 8.6 % Sector (7 companies) 64 17 % 10.7
Formulas and inputs

ROE: LTM attributable net income / Attributable equity at period end

LTM attributable net income
10,225.0
Attributable equity
48,667.0

ROIC: LTM EBIT × (1 − notional tax rate) / (Total equity + Financial debt − Cash)

LTM EBIT
13,743.0
Total equity
48,719.0
Financial debt
27,819.0
Cash and equivalents
5,711.0
Notional tax rate
0.2500

Gross margin: LTM gross profit / LTM revenue

LTM gross profit
48,106.0
LTM revenue
58,739.0

EBITDA margin: LTM EBITDA / LTM revenue

LTM EBITDA
19,476.0
LTM revenue
58,739.0

Cash conversion: (LTM operating cash flow − LTM capex) / LTM net income attributable

LTM operating cash flow
14,575.0
LTM capital expenditure (capex)
2,810.0
LTM attributable net income
10,225.0

Revenue growth: LTM revenue / LTM revenue a year earlier − 1

LTM revenue
58,739.0
Prior-year LTM revenue
54,073.0

Amounts in euros

Market capitalisation No data
Enterprise value (EV) No data
LTM revenue 51,982 M EUR
LTM EBITDA 17,236 M EUR
Net debt 18,815 M EUR

Creditor view

FactorValueCompared with PercentileWeightContribution
Net debt/EBITDA 1.1x Sector (7 companies) 79 33 % 26.2
Interest coverage 11.5x Sector (7 companies) 50 33 % 16.7
Debt/equity 0.6x Sector (6 companies) 75 33 % 25.0
Formulas and inputs

Net debt/EBITDA: (Financial debt − Cash) / LTM EBITDA

Financial debt
27,819.0
Cash and equivalents
5,711.0
LTM EBITDA
19,476.0

Interest coverage: LTM EBITDA / LTM interest expense

LTM EBITDA
19,476.0
LTM interest expense
1,694.0

Debt/equity: Financial debt / Total equity

Financial debt
27,819.0
Total equity
48,719.0

Outstanding bonds

The loaded data contain no outstanding bonds of this company.

Alerts

No alerts in this run.

Screens

ScreenResultConditions
Moderate leverage Passes Net debt/EBITDA ≤ 2.5x: value: 1.1x
Interest coverage ≥ 5.0x: value: 11.5x

Annual history (millions of USD)

2023
FY 31/12/2023
2024
FY 31/12/2024
2025
FY 31/12/2025
Revenue45,81154,07358,739
EBITDA13,58016,69119,476
Attributable net income5,9557,03510,225
Free cash flow8,9849,93711,765
Net debt—23,35522,108

Each fiscal year is labelled with the calendar year in which most of its months fall.

The scores summarise metrics compared with similar companies, and the alerts point to specific facts. Nothing shown here is a recommendation to buy or sell.